170 Chapter 5 REFERENCES 1. Reedijk AMJ, Coebergh JWW, de Groot-Kruseman HA, et al: Progress against childhood and adolescent acute lymphoblastic leukaemia in the Netherlands, 1990-2015. Leukemia 35:10011011, 2021 2. Pui CH, Evans WE: Treatment of acute lymphoblastic leukemia. N Engl J Med 354:166-78, 2006 3. Veerman AJ, Kamps WA, van den Berg H, et al: Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol 10:957-66, 2009 4. Irestorm E, Steur LMH, Kaspers GJL, et al: Fatigue trajectories during pediatric ALL therapy are associated with fatigue after treatment: a national longitudinal cohort study. Support Care Cancer 31:1, 2022 5. Steur LMH, Kaspers GJL, van Someren EJW, et al: The impact of maintenance therapy on sleep-wake rhythms and cancer-related fatigue in pediatric acute lymphoblastic leukemia. Support Care Cancer 28:5983-5993, 2020 6. Warris LT, van den Akker EL, Bierings MB, et al: Acute Activation of Metabolic Syndrome Components in Pediatric Acute Lymphoblastic Leukemia Patients Treated with Dexamethasone. PLoS One 11:e0158225, 2016 7. Reilly JJ, Brougham M, Montgomery C, et al: Effect of glucocorticoid therapy on energy intake in children treated for acute lymphoblastic leukemia. J Clin Endocrinol Metab 86:37425, 2001 8. Warris LT, van den Akker ELT, Bierings MB, et al: Eating behavior during dexamethasone treatment in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 64, 2017 9. Reilly JJ, Kelly A, Ness P, et al: Premature adiposity rebound in children treated for acute lymphoblastic leukemia. J Clin Endocrinol Metab 86:2775-8, 2001 10. Chow EJ, Pihoker C, Friedman DL, et al: Glucocorticoids and insulin resistance in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 60:621-6, 2013 11. te Winkel ML, van Beek RD, de Muinck Keizer-Schrama SM, et al: Pharmacogenetic risk factors for altered bone mineral density and body composition in pediatric acute lymphoblastic leukemia. Haematologica 95:752-9, 2010 12. Bluher M, Mantzoros CS: From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century. Metabolism 64:131-45, 2015 13. Kelesidis T, Kelesidis I, Chou S, et al: Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med 152:93-100, 2010 14. Misch M, Puthanveetil P: The Head-to-Toe Hormone: Leptin as an Extensive Modulator of Physiologic Systems. Int J Mol Sci 23, 2022 15. Miell JP, Englaro P, Blum WF: Dexamethasone induces an acute and sustained rise in circulating leptin levels in normal human subjects. Horm Metab Res 28:704-7, 1996 16. Larsson H, Ahren B: Short-term dexamethasone treatment increases plasma leptin independently of changes in insulin sensitivity in healthy women. J Clin Endocrinol Metab 81:4428-32, 1996 17. Zimberg IZ, Damaso A, Del Re M, et al: Short sleep duration and obesity: mechanisms and future perspectives. Cell Biochem Funct 30:524-9, 2012
RkJQdWJsaXNoZXIy MTk4NDMw